Stockscreener 앱 받기
0.00
100.00%
-3.18
Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스
Why Did ESPR Stock Surge 58% In Pre-Market Today? - Stocktwits
Esperion Therapeutics (ESPR): Goldman Sachs Group discloses 6.7% ownership stake - Stock Titan
Enterprise value to EBITDA forward of Esperion Therapeutics, Inc. – LS:A1W1SJ - TradingView
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
Esperion Therapeutics (ESPR) Holds Flat at $3.18 as Biotech Stock Consolidates Within Established Trading RangeOversold Bounce Ideas - dars.gov.et
Esperion Therapeutics (ESPR) Holds Steady at $3.18 as Range-Bound Trading PersistsIV Expansion Alert - vinanet.vn
Vanguard Capital Management (ESPR) reports 13.1M-share, 5.08% stake in Esperion - Stock Titan
Esperion Therapeutics Holds Steady Near Support as Investors Await CatalystsRip Sell Trade - vinanet.vn
Esperion Therapeutics Inc (ESPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Esperion Therapeutics Inc (ESPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Esperion Therapeutics Inc (ESPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ESPR|Esperion Therapeutics Inc|Price:3.180| - TradingKey
Esperion Therapeutics Inc (ESPR) Cash Flow - TradingKey
Esperion Therapeutics (ESPR) Holds Flat at $3.18 as Stock Consolidates in Narrow RangeRTH Profile - dars.gov.et
Esperion Therapeutics, Inc. Revenue Breakdown – LSX:A1W1SJ - TradingView
Esperion Therapeutics, Inc. SEC Filing (Jul 23, 2026) - Stock Titan
Akin, an Elite Global Law Firm - akingump.com
Esperion Therapeutics (ESPR) Stock Forecast & Analyst Ratings - Moomoo
Esperion Therapeutics Holds Steady at $3.18 as Support and Resistance Levels TightenDelta Hedging - vinanet.vn
[EFFECT] Esperion Therapeutics, Inc. SEC Filing - Stock Titan
Esperion Therapeutics, Inc. SEC Filing (Jul 16, 2026) - Stock Titan
Esperion Therapeutics Inc (NASDAQ: ESPR) Share Price, ESPR Stock News, ESPR Share Price & Updates - Kalkine
PFE6265887 Bond Coupon Profile — Rate & Payments - TradingView
Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake - Stock Titan
BioPharma Credit, Affiliate Lend $400 Million to Archimed for Esperion Therapeutics Deal - Moomoo
Enterprise value to revenue forward of Esperion Therapeutics, Inc. – DUS:0ET - TradingView
Key facts: Esperion to Delist from Nasdaq; Merger Creates $100M CVR - TradingView
REGBioPharma Credit PLCUPDATE ON ARCHIMED ESPERION ACQUISITION - TradingView
PFE6265887 Bond Risk Profile - TradingView
Esperion Therapeutics, Inc.(NasdaqGM: ESPR) dropped from S&P Global BMI Index - marketscreener.com
Esperion Therapeutics, Inc.(NasdaqGM: ESPR) dropped from S&P TMI Index - marketscreener.com
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Form 4 Esperion Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
PFE6265887 Bond Profile — Key Metrics - TradingView
Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs - Stock Titan
Esperion Therapeutics (ESPR) director exits equity as merger pays $3.16 plus CVRs - Stock Titan
Esperion Therapeutics (ESPR) director converts shares and options into $3.16 cash and CVRs - Stock Titan
Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs in merger - Stock Titan
Esperion Therapeutics (ESPR) director exits holdings in $3.16-per-share cash and CVR merger - Stock Titan
Esperion Therapeutics (ESPR) CCO swaps 424,536 RSUs for $3.16 cash plus CVRs - Stock Titan
Esperion Therapeutics (ESPR) CLO equity cashed out at $3.16 plus CVRs - Stock Titan
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity - Stock Titan
Esperion Therapeutics (ESPR) CEO exits equity in cash-and-CVR merger payout - Stock Titan
An unknown funds, managed by ArchiMed SAS completed the acquisition of Esperion Therapeutics, Inc. from Wasatch Advisors LP, BlackRock, Inc. and others. - marketscreener.com
[POSASR] Esperion Therapeutics, Inc. SEC Filing - Stock Titan
Esperion Therapeutics, Inc. SEC Filing (Jul 13, 2026) - Stock Titan
Esperion Therapeutics, Inc. Announces Board Changes - marketscreener.com
Esperion Therapeutics Acquired by Essence Parent Inc.: Merger, NASDAQ Delisting, and Contingent Value Rights Details – Minichart - Minichart
Esperion Therapeutics (ESPR) moves to remove its Nasdaq listing - Stock Titan
Esperion Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView
Esperion Therapeutics, Inc.(NasdaqGM: ESPR) dropped from NASDAQ Biotechnology Index - marketscreener.com
Esperion Therapeutics, Inc. (ESPR) Latest Stock News & Headlines - Yahoo Finance
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger - TradingView
ESPR Stock Price, Quote & Chart - ChartMill
Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Esperion shareholders approve merger with Essence Parent Inc. - The Globe and Mail
Esperion Therapeutics Stockholders Approve Merger with Essence Parent Inc. – Key SEC 8-K Filing Details - Minichart
Esperion Therapeutics (ESPR) investors back merger with Essence Parent in special meeting vote - Stock Titan
1.24%
자본화:
|
볼륨(24시간):